News & Events about Biohaven Pharmaceutical Holding Company Ltd.
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn., Jan. 6, 2023 NEW HAVEN, Conn., Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced thatVlad Coric...
Mike Heffernan appointed Chairman of NMD Pharmas Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen several successful IPOs and trade sales Aarhus, Denmark, 3 January 2023 NMD Pharma A/S, a ...
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire NEW HAVEN, Conn., Oct. 25, 2022 NEW HAVEN...
Biohaven Announces Pricing of Public Offering of Common Shares Biohaven Announces Pricing of Public Offering of Common Shares PR Newswire NEW HAVEN, Conn., Oct. 20, 2022 NEW HAVEN, Conn., Oct. 20, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ('Biohaven') announced today the pricing of...
Business Wire
4 months ago
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. The acquisition brings to...